BeOne Medicines (BEIGF) Operating Expenses (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Operating Expenses data on file, last reported at $1.1 billion in Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.1 billion, up 16.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 14.2% YoY), and the FY2025 annual result was $4.2 billion, up 11.71% from the prior year.
• Operating Expenses fell to $1.1 billion in Q1 2026 per BEIGF's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $1.2 billion in Q4 2025 and troughed at $562.2 million in Q4 2022.
• A 5-year average of $900.8 million and a median of $898.2 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 148.77% in 2022, then retreated 1.69% in 2023.
• A 5-year view of Operating Expenses shows it stood at $562.2 million in 2022, then soared by 62.27% to $912.4 million in 2023, then advanced by 14.72% to $1.0 billion in 2024, then climbed by 11.85% to $1.2 billion in 2025, then decreased by 6.35% to $1.1 billion in 2026.
• Business Quant data shows BEIGF's Operating Expenses at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.